French watchdog warns about use of Trump-backed virus drug
The French drugs agency warned doctors for a second time Saturday about using hydroxychloroquine, the drug championed by US President Donald Trump as a "game changer" in the fight against COVID-19, as the number of cases of worrying side effects continued to rise.
The agency, known by its initials ANSM, had already issued a "signal of vigilance" about the anti-malaria drug which is also used to treat lupus and rheumatoid arthritis.
It said over half the 321 cases of "undesirable side-effects" from treatments being used against the coronavirus came from hydroxychloroquine and the antibiotic azithromycin, which is used with it.
ANSM said that overall since the beginning of the epidemic, serious side-effects had been reported in "80 percent of the cases" reported.
It said all four deaths in French hospitals associated with side-effects from such treatments had been linked to hydroxychloroquine.
The use of the controversial combination has hit the headlines after the flamboyant French infectious diseases specialist Didier Raoult published two small studies showing that it could work against the virus, for which there is no known treatment.
But despite growing calls in France for the use of the drugs to be widened, other experts have remained highly sceptical of Professor Roault's claims, and have pointed to the danger of heart attacks.
On Thursday, the European Medicines Agency added its voice to growing concern about the anti-malarial drug.
"Recent studies have reported serious, in some cases fatal, heart rhythm problems with chloroquine or hydroxychloroquine, particularly when taken at high doses or in combination with the antibiotic azithromycin," the Amsterdam-based body said.
It added that there was no indication that its use was beneficial against the virus.
The French ANSM said 42 percent of the overall worrying side-effects concerned Kaletra, an anti-retroviral drug which combines lopinavir and ritonavir.
Hydroxychloroquine is known to cause electrical problems like arrhythmia in the hearts of some patients, which can sometimes be fatal.
ANSM chief Dominique Martin had earlier told AFP that "people sick with COVID tend to have more fragile hearts" and were thus more likely to have problems with drugs which affect cardiac health.
Comments
See Also
The agency, known by its initials ANSM, had already issued a "signal of vigilance" about the anti-malaria drug which is also used to treat lupus and rheumatoid arthritis.
It said over half the 321 cases of "undesirable side-effects" from treatments being used against the coronavirus came from hydroxychloroquine and the antibiotic azithromycin, which is used with it.
ANSM said that overall since the beginning of the epidemic, serious side-effects had been reported in "80 percent of the cases" reported.
It said all four deaths in French hospitals associated with side-effects from such treatments had been linked to hydroxychloroquine.
The use of the controversial combination has hit the headlines after the flamboyant French infectious diseases specialist Didier Raoult published two small studies showing that it could work against the virus, for which there is no known treatment.
But despite growing calls in France for the use of the drugs to be widened, other experts have remained highly sceptical of Professor Roault's claims, and have pointed to the danger of heart attacks.
On Thursday, the European Medicines Agency added its voice to growing concern about the anti-malarial drug.
"Recent studies have reported serious, in some cases fatal, heart rhythm problems with chloroquine or hydroxychloroquine, particularly when taken at high doses or in combination with the antibiotic azithromycin," the Amsterdam-based body said.
It added that there was no indication that its use was beneficial against the virus.
The French ANSM said 42 percent of the overall worrying side-effects concerned Kaletra, an anti-retroviral drug which combines lopinavir and ritonavir.
Hydroxychloroquine is known to cause electrical problems like arrhythmia in the hearts of some patients, which can sometimes be fatal.
ANSM chief Dominique Martin had earlier told AFP that "people sick with COVID tend to have more fragile hearts" and were thus more likely to have problems with drugs which affect cardiac health.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.